On behalf of AIM, Dr. Geoffrey Lim, a dermatologic surgeon at SkinMed Institute in Lone Tree, Colorado, conducted an interview with Dr. Jason Luke, Associate Professor of Medicine at the University of Pittsburgh Medical Center. Dr. Luke, a leading medical oncologist and co-author of a pivotal study on adjuvant therapy, shared insights on Stage II melanoma.

Their discussion covered frequently asked questions, which Stage II patients qualify for adjuvant therapy, and the benefits and drawbacks of adjuvant therapy compared to active surveillance. This resource is designed to aid you, your loved ones, and your oncology care team in making informed decisions about post-surgery steps. Explore our latest flip magazine for insights into the newest advancements in adjuvant therapy for Stage II melanoma.